Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Castration-resistant prostate cancer (CRPC) presents a significant therapeutic challenge, often characterized by the emergence of resistance to androgen receptor (AR)-targeted therapies. The scientific community continues to seek innovative solutions, and ODM-201 (CAS: 1297538-32-9) has emerged as a highly promising compound. As a leading provider of advanced pharmaceutical intermediates, we are committed to supplying the materials necessary for pioneering research in this critical area of oncology.
ODM-201 is a potent, novel AR inhibitor developed to address the limitations of existing treatments for CRPC. Its mechanism of action focuses on inhibiting AR signaling, a pathway that remains crucial for prostate cancer cell growth even after castration. What sets ODM-201 apart is its remarkable efficacy against AR mutations that typically confer resistance to second-generation antiandrogens. This includes its potent antagonistic activity against the F876L mutation, which has been identified as a key factor in treatment failure. This ability to overcome common resistance pathways makes it an invaluable pharmaceutical intermediate for drug developers.
Beyond its effectiveness against resistant AR variants, ODM-201 boasts a favorable safety profile. Preclinical studies have indicated negligible brain penetration, a characteristic that significantly lowers the risk of neurological side effects, such as seizures, which can be a concern with some other AR-targeting agents. This improved tolerability can lead to better patient outcomes and adherence to treatment regimens. Consequently, understanding the role and availability of ODM-201 is crucial for those engaged in the development of advanced prostate cancer therapies.
For researchers, formulators, and procurement specialists, securing a reliable source for high-quality ODM-201 is essential. We are a dedicated manufacturer and supplier based in China, offering this vital pharmaceutical intermediate with a strong emphasis on purity and consistency. If you are investigating new treatments for CRPC or require this advanced compound for your research, we invite you to inquire about our ODM-201 offerings. Partner with us to access this cutting-edge material and advance your oncology research.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
